SEC Form 4 · accession 0001615774-18-001626
CALMARE THERAPEUTICS Inc · CTTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Conrad F Mir
Officer — President & CEO · Director
Period of report
Feb 12, 2018
Accepted (ET)
Mar 6, 2018 · 1:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000102198
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 12, 2018 | M | 1,000,000 | $0.08 | A | 1,440,751 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionF1 | $0.08 | Feb 12, 2018 | M | 1,000,000 | A | — | — | Common Stock | 1,000,000 | 1,000,000 | D |
Explanation of responses
- F1A stock option to purchase 1,000,000 shares at an exercise price of $0.08 was granted on 10/1/2013. 20% of this option vested on 10/1/2013, 10/1/2014, 10/1/2015, 10/1/2016 and 10/1/2017, respectively.